Intellia Therapeutics NTLA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's operating cash flow?
- Intellia Therapeutics (NTLA) reported operating cash flow of -$117.35M in Q1 2026.
- How has Intellia Therapeutics's operating cash flow changed year-over-year?
- Intellia Therapeutics's operating cash flow increased by 21.2% year-over-year, from -$148.93M to -$117.35M.
- What is the long-term trend for Intellia Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Intellia Therapeutics's operating cash flow has grown at a 15.1% compound annual growth rate (CAGR), from -$225.03M to -$394.74M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.